ALK and non-small cell lung carcinoma: Entire cohort: In univariate analysis, no baseline CNS involvement (p = 0.04), using osimertinib (p = 0.01), using osimertinib/first-generation EGFR TKI plus chemotherapy/ALK inhibitor in ALK-positive NSCLC cases (p = 0.005) were predictors of superior PFS, while the only absence of CNS involvement was an indicator of better OS.